| Journal of Clinical Medicine | |
| Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review | |
| Florence Tenenbaum1  Anne-Ségolène Cottereau2  Catherine Brezault3  Lola-Jade Palmieri3  Solène Dermine3  Baptiste Camus3  Romain Coriat3  | |
| [1] Department of Nuclear Medicine, Cochin Hospital, AP-HP Centre, 27 rue du Faubourg Saint- Jacques, 75014 Paris, France;Faculté de Médecine, Université de Paris, 75006 Paris, France;Gastroenterology and Digestive Oncology Unit, Cochin Hospital, AP-HP Centre, 27 rue du Faubourg Saint- Jacques, 75014 Paris, France; | |
| 关键词: neuroendocrine tumors; neoplasm metastasis; PRRT; peptide receptor radionuclide therapy; gastroenteropancreatic tumor; pulmonary tumor; | |
| DOI : 10.3390/jcm10061267 | |
| 来源: DOAJ | |
【 摘 要 】
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are 90Y-DOTATOC and 177Lu-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared177Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.
【 授权许可】
Unknown